Neuroblastoma: a clinical challenge and biologic puzzle
1995; Wiley; Volume: 45; Issue: 3 Linguagem: Inglês
10.3322/canjclin.45.3.179
ISSN1542-4863
Autores Tópico(s)Neurofibromatosis and Schwannoma Cases
ResumoCA: A Cancer Journal for CliniciansVolume 45, Issue 3 p. 179-192 ArticleFree Access Neuroblastoma: A clinical challenge and biologic puzzle Katherine K. Matthay MD, Katherine K. Matthay MD Professor of Pediatrics and the Director of Pediatric Oncology at the University of California School of Medicine, San Francisco, CaliforniaSearch for more papers by this author Katherine K. Matthay MD, Katherine K. Matthay MD Professor of Pediatrics and the Director of Pediatric Oncology at the University of California School of Medicine, San Francisco, CaliforniaSearch for more papers by this author First published: May/June 1995 https://doi.org/10.3322/canjclin.45.3.179Citations: 65AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Young JL Jr Ries LG, Silverberg E, et al: Cancer incidence, survival and mortality for children younger than age 15 years. Cancer 1986; 58: 598– 602. 2 Matthay KK: Congenital malignant disorders, in HW Taesch, RA Ballard, ME Avery (eds): Schaffer & Avery's Diseases of the Newborn, ed. 6. Philadelphia, WB Saunders Co., 1990. 3 Kramer S, Ward E, Meadows AT, Malone KE: Medical and drug risk factors associated with neuroblastoma: A case-control study. J Natl Cancer Inst 1987; 78: 797– 804. 4 Goodman SN: Neuroblastoma screening data: An epidemiologic analysis. Am J Dis Child 1991; 145: 1415– 1422. 5 Murphy SB, Cohn SL, Craft AW, et al: Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on neuroblastoma screening. Lancet 1991; 337: 344– 346. 6 Kushner BH, Gilbert F, Helson L: Familial neuroblastoma: Case reports, literature review, and etiologic considerations. Cancer 1986; 57: 1887– 1893. 7 Laureys G, Speleman F, Opdennakker G, et al: Constitutional translocation t(1;17)(p36;q12–21) in a patient with neuroblastoma. Genes Chromosom Cancer 1990; 2: 252– 254. 8 Biegel JA, White PS, Marshall HN, et al: Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet 1993; 52: 176– 182. 9 Brodeur GM, Green AA, Hayes FA, et al: Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981; 41: 4678– 4686. 10 Hayashi Y, Kanda N, Inaba T, et al: Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989; 63: 126– 132. 11 Christiansen H, Lampert F: Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988; 57: 121– 126. 12 Fong CJ, Dracopoli NC, White PS, et al: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N- myc amplification. Proc Natl Acad Sci USA 1989; 86: 3753– 3757. 13 Suzuki T, Yokota J, Mugishima H, et al: Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 1989; 49: 1095– 1098. 14 Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N- myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581– 591. 15 Schwab M, Ellison J, Busch M, et al: Enhanced expression of the human gene N- myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984; 81: 4940– 4944. 16 Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121– 1124. 17 Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N- myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111– 1116. 18 Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N- myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. Am J Pathol 1993; 142: 1339– 1346. 19 Seeger RC, Wada R, Brodeur GM, et al: Expression of N- myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988; 271: 41– 49. 20 Crabbe DC, Peters J, Seeger RC: Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Path 1992; 1: 229– 234. 21 Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847– 854. 22 Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85: 377– 384. 23 Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children with neuroblastoma: Serum concentration parallels disease stage and predicts survival. J Clin Invest 1990; 85: 1555– 1559. 24 Cohen PS, Cooper MJ, Helman LJ, et al: Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 1990; 50: 6055– 6061. 25 Shimada H, Chatten J, Newton WA Jr: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405– 416. 26 Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. Hum Pathol 1988; 19: 1187– 1198. 27 Brodeur GM, Castsleberry RP: Neuroblastoma, in PA Pizzo, DG Poplack (eds): Principles and Practice of Pediatric Oncology, ed 2. Philadelphia, JB Lippincott Co., 1993, pp 739– 767. 28 Matthay KK: Neuroblastoma, in C Pochedly (ed): Neoplastic Diseases of Childhood. Chur, Switzerland, Harwood Academic, 1994, pp 735– 778. 29 Mitchell CH, Sinatra FR, Crast FW, et al: Intractable watery diarrhea, ganglioneuroblastoma, and vasoactive intestinal peptide. J Pediatr 1976; 89: 593– 595. 30 Bray PF, Ziter FA, Lahey ME, Myers GG: The coincidence of neuroblastoma and acute cerebellar encephalopathy. J Pediatr 1969; 75: 983– 990. 31 Fisher PG, Wechsler DS, Singer HS: Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 1994; 10: 309– 312. 32 Moss TJ, Sanders DG: Detection of neuroblastoma cells in blood. J Clin Oncol 1990; 8: 736– 740. 33 Hayes FA, Green A, Hustu HO, Kumar M: Surgicopathologic staging of neuroblastoma: Prognostic significance of regional lymph node metastases. J Pediatr 1983; 102: 59– 62. 34 Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991; 324: 219– 226. 35 Lumbroso JD, Guermazi F, Hartmann O, et al: Meta-iodobenzylguanidine (MIBG) scans in neuroblastoma: Sensitivity and specificity: A review of 115 scans. Prog Clin Biol Res 1988; 271: 689– 705. 36 Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR: Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987; 28: 308– 314. 37 Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 1971; 27: 374– 378. 38 American Joint Committee on Cancer: Neuroblastoma, in Manual for Staging of Cancer, ed 2. Philadelphia, JB Lippincott, 1983, p 237. 39 Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874– 1881. 40 Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466– 1477. 41 Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7: 236– 244. 42 Evans AR, Brand W, de Lorimier A, et al: Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide: A report from the Children's Cancer Study Group. Am J Clin Oncol 1984; 7: 3– 7. 43 Haase GM, Atkinson JB, Stram DO, et al: Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the International Staging Systems. J Pediatr Surg 1995; 30: 289– 295. 44 Matthay K, Seeger R, Haase G, et al: Treatment and outcome for stage III neuroblastoma based on prospective biologic staging. Med Pediatr Oncol 1994; 23: 173. Abstract. 45 Matthay K, Seeger R, Stram D, et al: Prognosis for stage IV neuroblastoma less than one year at diagnosis: A prospective Childrens Cancer Group study. Proc Am Soc Clin Oncol 1995. in press. 46 Evans AE, Chatten J, D'Angio GJ, et al: A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 1980; 45: 833– 839. 47 Haas D, Ablin AR, Miller C, et al: Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988; 62: 818– 825. 48 Nickerson HJ, Nesbit ME, Grosfeld JL, et al: Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 1985; 13: 261– 268. 49 Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050– 1058. 50 Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 1984; 2: 742– 747. 51 Bernard JL, Philip T, Zucker JM, et al: Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: An effective alternating non-cross-resistant regimen?. J Clin Oncol 1987; 5: 1952– 1959. 52 Campbell LA, Seeger RC, Harris RE, et al: Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993; 11: 623– 629. 53 Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12: 2607– 2613. 54 Stram DO, Matthay KK, O'Leary M, et al: Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res 1994; 385: 287– 291. 55 Castleberry RP, Cantor AB, Green AA, et al: Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1616– 1620. 56 Seeger RC, Villablanca JG, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1991; 366: 527– 533. 57 Pole JG, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 152– 158. 58 Philip T, Zucker JM, Bernard JL, et al.: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup?. J Clin Oncol 1991; 9: 1037– 1044. 59 Kushner BH, O'Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991; 9: 274– 279. 60 Dini G, Lanino E, Garaventa A, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases. J Clin Oncol 1991; 9: 962– 969. 61 Shuster JJ, Cantor AB, McWilliams N, et al: The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991; 9: 1045– 1049. 62 Brenner MK, Rill DR, Moen RC, et al: Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 1994; 716: 204– 14. 63 Reynolds CP, Seeger RC, Vo DD, et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46: 5882– 5886. 64 Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382– 2389. 65 Matthay KK, Atkinson JB, Stram DO, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study. J Clin Oncol 1993; 11: 2226– 2233. 66 Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430– 1440. 67 Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994; 12: 184– 193. 68 Hank JA, Surfus J, Gan J, et al: Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994; 15: 29– 37. 69 Cheung NK, Munn D, Kushner BH, et al: Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Int J Rad Appl Instrum 1989; 16: 111– 120. 70 Lashford LS, Lewis IJ, Fielding SL, et al: Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group Investigation. J Clin Oncol 1992; 10: 1889– 1896. 71 Voute PA, Hoefnagel CA, de Kraker J, et al: Results of treatment with 131I-metaiodobenzyl-guanidine (131I-MIBG) in patients with neuroblastoma: Future prospects of zetotherapy. Prog Clin Biol Res 1991; 366: 439– 445. 72 Matthay KK, Huberty JP, Hattner RS, et al: Efficacy and safety of 131I-metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991; 35: 244– 247. 73 Reynolds CP, Kane DJ, Einhorn PA, et al: Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991; 366: 203– 211. 74 Finklestein JZ, Krailo MD, Lenarsky C, et al: 13-Cis-retinoic acid in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992; 20: 307– 311. Citing Literature Volume45, Issue3May/June 1995Pages 179-192 ReferencesRelatedInformation
Referência(s)